John P. Leonard1, Marek Trneny2, Nathan H. Fowler3, Xiaonan Hong4, Jun Zhu5, Huilai Zhang6, Fritz Offner7, Adriana Scheliga8, Grzegorz Nowakowski9, Antonio Pinto10, Francesca Re11, Laura Maria Fogliatto12, Phillip Scheinberg13, Ian Flinn14, Claudia Moreira15, Myron Czuczman16, Stacey Kalambakas16, Pierre Fustier17, Chengqing Wu16, John Gribben18, Koji Izutsu19
(1.Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States of America, 2.Charles University Hospital, Prague, Czech Republic, 3.The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 4.Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, 5.Beijing Cancer Hospital, Beijing, People's Republic of China, 6.Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China, 7.UZ Gent, Gent, Kingdom of Belgium, 8.INCA Instituto Nacional de Cancer, Rio de Janeiro, Federative Republic of Brazil, 9.Mayo Clinic, Rochester, MN, United States of America, 10.Istituto Nazionale Per Lo Studio E La Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Italian Republic, 11.Azienda Ospedaliero-Universitaria di Parma, Parma, Italian Republic, 12.Hospital de Clinicas de Porto Alegre, Porto Alegre, Federative Republic of Brazil, 13.Division of Hematology, Hospital A Beneficencia Portuguesa, Sao Paulo, Federative Republic of Brazil, 14.SCRI Tennessee Oncology Nashville, Nashville, TN, United States of America, 15.Instituto Portugues de Oncologia do Porto Francisco Gentil Epe, Porto, Portuguese Republic, 16.Celgene Corporation, Summit, NJ, United States of America, 17.Celgene Corporation, Boudry, Swiss Confederation, 18.Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom of Great Britain and Northern Ireland, 19.National Cancer Center Hospital, Tokyo, Japan)
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.
